🧾 What This Document Is

This is a 6-K form, which is a report foreign companies (like Belite Bio, incorporated in the Cayman Islands) file with the SEC to announce important events. This specific filing is a press release announcing that the company's full-year 2025 annual report is now available on its website. This is a routine but required disclosure under Nasdaq rules to ensure shareholders have easy access to financial statements.

👉 Why it matters: It's a signal of transparency and compliance. For investors, it’s a formal prompt that the detailed yearly financials—audited by an independent firm—are ready for review.

🏢 What The Company Does

In simple terms… Belite Bio is a biotech startup working on new drugs for serious eye diseases that cause blindness, like Stargardt disease and the "dry" form of macular degeneration.

They are clinical-stage, meaning their main drug candidate, tinlarebant, is still being tested in people and isn't approved for sale yet. Their therapy is an oral pill designed to stop toxic buildup in the eye that damages the retina.

👉 Why it matters: The company's entire value currently hinges on the success of its drug trials. This isn't a company selling products yet; it's a research and development bet on future medicines.

💰 Financial Highlights (Contextual)

While this press release doesn't detail the financial results from the 20-F, the existence of the filing is the key point. The Form 20-F itself contains Belite Bio's audited financial statements for the year ended December 31, 2025. Key numbers investors would find inside that document include:

Cash position: How much money they have left to fund operations.
Research & Development (R&D) expenses: The cost of running their drug trials.
Net loss: The standard for a pre-revenue clinical biotech.

👉 Why it matters: For a clinical-stage biotech, the most critical number is its cash runway—how long it can operate before it needs to raise more money. This annual report provides that definitive snapshot.

🧪 Pipeline & Clinical Trials

Belite Bio's story is defined by its two pivotal drug trials for tinlarebant:

DRAGON & DRAGON II: Phase 3 and Phase 2/3 trials in adolescents with Stargardt disease (STGD1).
PHOENIX: A Phase 3 trial in adults with Geographic Atrophy (GA), a late-stage form of dry age-related macular degeneration.

👉 Why it matters: These trials are the company's "make or break" milestones. Positive results would dramatically increase the company's value and bring the drug closer to market. The annual report likely contains updated details on trial timelines and spending.

📅 Key Dates & Logistics

Annual Report Filed: March 31, 2026
Access: Available on the company website: https://www.belitebio.com
Hard Copies: Shareholders can request a free printed copy.
Trigger: This announcement was made to comply with Nasdaq Listing Rule 5250(d)(1)(C).

⚖️ Big Picture

👍 Strengths:

Focused Mission: Targets large, unmet medical needs in retinal disease.
Oral Therapy Advantage: A pill (tinlarebant) is much easier to administer than the current standard of care, which often involves injections into the eye.
Advanced Stage: Has Phase 3 trials ongoing, putting it closer to potential commercialization than earlier-stage biotechs.

⚠️ Risks:

Binary Outcome Risk: The company's success depends almost entirely on positive clinical trial results. Failure would be devastating.
Cash Burn: As a R&D company, it spends heavily without revenue, leading to recurring losses and potential future shareholder dilution.
Competition: Other large pharmaceutical companies are also developing treatments for the same eye diseases.

🔮 What's Next

The next major catalysts for Belite Bio will be the readout of data from its DRAGON II and PHOENIX trials. The company will use the capital reflected in its 20-F to fund these final, expensive stages of research. The path forward is singular: complete trials, analyze results, and if successful, seek regulatory approval to bring their drug to patients.

🧠 The Analogy

Belite Bio is like a team of engineers building a revolutionary new bridge. The annual report (20-F) is their detailed public ledger, showing everyone how much money they have left for construction and what they've spent so far. The clinical trials (DRAGON, PHOENIX) are the critical stress tests of the bridge's design. Until those tests are passed successfully and the bridge opens (drug approval), the company's value is based almost entirely on the promise of its blueprint, not its finished product.

📇 Key Contacts & People

Media and Investor Relations Contact: Jennifer Wu
- Email: [email protected]
Media and Investor Relations Contact: Julie Fallon
- Email: [email protected]

🧩 Final Takeaway

This filing is a compliance formality, but the important news is that Belite Bio's 2025 audited financial report is now public. For this clinical-stage biotech, that report is the official record of the cash fueling its high-stakes race to develop new drugs for blinding eye diseases. The real story will unfold when its major clinical trial results are released.

BELITE BIO, INC — 6-K Filing